<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2203210613
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Oramorph
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MORPHINE SULFATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        30.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" L. Molteni &amp; C dei F. LLi Alitti Societa di Esercizio" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             L. Molteni & C dei F. LLi Alitti Societa di Esercizio
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 653]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            YAHMAA MEDICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            L Molteni and C dei F lli Alitti Societa di Esercizio SpA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N02AA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The full name of your medicine is Oramorph 20 mg/ml oral solution. In this leaflet the shorter name Oramorph is used.<br />&bull; This medicine has been prescribed for you for relief of severe pain<br />&bull; It contains a medicine called morphine sulfate, which belongs to a class of medicines called opioids, which are &lsquo;pain relievers&rsquo;<br />&bull; This medicine has been prescribed for you and should not be given to anyone else<br />&bull; Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Oramorph if:<br />&bull; You are allergic (hypersensitive) to morphine sulfate or any of the other ingredients of this medicine (listed in section 6 below)<br />&bull; You have problems with your lungs or breathing such as &lsquo;hypoventilation&rsquo; or &lsquo;Chronic Obstructive Pulmonary Disease&rsquo; (COPD)<br />&bull; You are having an asthma attack<br />&bull; You have sudden or recent liver problems<br />&bull; You have recently had a head injury<br />&bull; You have something called &lsquo;phaeochromocytoma&rsquo;. This is a rare tumour which is not malignant<br />&bull; You have fits (convulsions) or increased pressure inside your skull<br />&bull; The person taking the medicine is in a deep and prolonged unconscious state (coma)<br />&bull; You are addicted to alcohol or have recently consumed large amounts of alcohol<br />&bull; You are taking or have in the last two weeks taken medication to treat depression such as monoamine oxidase inhibitors (MAOIs)<br />&bull; You have paralytic ileus (loss of intestinal movement)<br />Do not take Oramorph if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist.</p><p>Take special care with Oramorph<br />Check with your doctor or pharmacist before taking your medicine if you:<br />&bull; Are pregnant, trying to become pregnant or if you are breast-feeding<br />&bull; Have had an operation within the last 24 hours<br />&bull; Have a particular lung problem that causes shortness of breath called emphysema or you have heart failure<br />&bull; Have shock (circulatory failure)<br />&bull; Have asthma<br />&bull; Have gall bladder problems<br />&bull; Have long term (chronic) liver or kidney problems<br />&bull; Are a man who has prostate problems<br />&bull; Have an under-active thyroid gland or swelling of your skin (myxoedema)<br />&bull; Have an unusually curved spine (kyphoscoliosis)<br />&bull; Have bowel problems<br />&bull; Have an under-active adrenal gland (adrenocortical insufficiency)<br />&bull; Are very overweight<br />&bull; Are or have ever been addicted to opioids, alcohol, prescription medicines, or illegal drugs.<br />&bull; Have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating, when you have stopped taking alcohol or drugs.<br />If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Oramorph<br />Warnings and precautions<br />Talk to your doctor or pharmacist if you experience any of the following symptoms while you are taking Oramorph:<br />&bull; Increased sensitivity to pain despite the fact that you are taking increasing doses (hyperalgesia). Your doctor will decide whether you will need a change in dose or a change in strong analgesic (&ldquo;painkiller&rdquo;) (see section 3).<br />&bull; Weakness, fatigue, lack of appetite, nausea, vomiting or low blood pressure. This may be a symptom of the adrenal glands producing too little of the hormone cortisol, and you may need to take hormone supplement.<br />&bull; Loss of libido, impotence, cessation of menstruation. This may be because of decreased sex hormone production.<br />&bull; You feel you need to take more of Oramorph to get the same level of pain relief, this may mean you are becoming tolerant to the effects of this medicine or are becoming addicted to it. Speak to your prescriber who will discuss your treatment and may change your dose or switch you to an alternative pain reliever<br />&bull; Taking this medicine regularly, particularly for a long time, can lead to addiction. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.<br />&bull; Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your prescriber about your treatment.<br />&bull; Addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your prescriber will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms.<br />&bull; Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else.<br />&bull; Taking higher doses or more frequent doses of opioid, may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death.</p><p>Other medicines and Oramorph<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal medicines. This is because Oramorph can affect the way some other medicines work. Also some other medicines can affect the way Oramorph works.<br />In particular tell your doctor or pharmacist if you are taking any of the following medicines:<br />&bull; Medicines to help you sleep, make you feel less anxious or calm you down such as tranquilisers, hypnotics, sedatives, antipsychotics or tricyclic antidepressants<br />- Taking Oramorph together with sedative medicines such as benzodiazepines or related medicines increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, taking Oramorph together with these types of medicines should only be considered when other treatment options are not possible.<br />However if your doctor does prescribe Oramorph with sedative medicines the dose and duration of taking the treatments together should be limited by your doctor.<br />- Please tell your doctor about all sedative medicines you are taking, and follow your doctor&rsquo;s dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor if you experience these symptoms<br />&bull; Anaesthetics - used during operations<br />&bull; Domperidone, metoclopramide or phenothiazine - medicines for feeling sick (nausea) and being sick (vomiting)<br />&bull; Mexiletine and esmolol - for controlling heart rhythm<br />&bull; Ritonavir - for HIV infections<br />&bull; Cimetidine - for stomach ulcers, indigestion or heartburn<br />&bull; Monoamine oxidase inhibitors (MAOIs) - for depression<br />&bull; Rifampicin - used to treat tuberculosis and other infections<br />&bull; Gabapentin - for epilepsy and long lasting pain caused by damage to the nerves<br />&bull; Medicines used to treat blood clots (e.g. clopidogrel, prasugrel, ticagrelor) - may have delayed and decreased effect when taken together with morphine.<br />Taking Oramorph with food and drink<br />You should avoid alcohol whilst taking this medicine.<br />Pregnancy and breast-feeding<br />Do not take Oramorph if you are pregnant or think you might be pregnant unless you have discussed this with your prescriber and the benefits of treatment are considered to outweigh the potential harm to the baby. If you use Oramorph during pregnancy, your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated.<br />Do not take Oramorph while you are breast-feeding as morphine sulfate passes into breast milk and will affect your baby.<br />Operations and anaesthetics<br />Tell your doctor or pharmacist if you are due to have an operation or anaesthetic or if you have had an operation or an anaesthetic within the last 24 hours.<br />Driving and using machines<br />Do not drive, cycle or use any tools or machines while taking this medicine. This is because you may feel sleepy and less alert while taking this medicine &ndash; even at normal doses.<br />Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine.<br />Important information about some of the ingredients of Oramorph<br />- Sodium benzoate<br />This medicine also contains 1 mg sodium benzoate (E211) in each 1 ml (16 drops).</p><p>Sodium benzoate may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).<br />- Sodium<br />This medicine contains less than 1 mmol sodium (23 mg) per 1 ml (16 drops), that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br />Your doctor should have discussed with you how long the course of this medicine will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine.<br />Method and/or route(s) of administration<br />&bull; Take this medicine by mouth only<br />&bull; Open the cap of the bottle by pushing down and twisting at the same time.<br />&bull; To measure the dose count the drops from the 20 ml bottle (1 drop = 1.25 mg morphine sulfate):<br />4 drops = 5 mg morphine<br />8 drops = 10 mg morphine<br />16 drops = 20 mg morphine<br />24 drops = 30 mg morphine<br />&bull; Close the bottle firmly with the cap once you have poured the medicine.<br />&bull; You may prefer to add your dose to a soft drink. If you do this, it should be swallowed immediately after mixing<br />Do not drink directly from the bottle as this may result in you taking the incorrect dose (too little or too much). Taking too much may result in an overdose with potential for serious consequences including unconsciousness and even death.<br />Dosage<br />Your doctor will decide the amount of medicine to give you.<br />Adults<br />&bull; The most that should be taken is 8 - 16 drops (10-20 mg) every 4 hours<br />Paediatric population<br />Adolescents 13 - 18 years<br />&bull; The most that should be taken is 4 - 16 drops (5-20 mg) every 4 hours<br />Children 6 to 12 years<br />&bull; The most that should be taken is 4 - 8 drops (5-10 mg) every four hours<br />Children 1 to 5 years<br />&bull; The most that should be taken is 4 drops (5 mg) every four hours<br />Children under 1 year<br />&bull; Do not give this medicine to children under 1 year<br />Being given more or less of this medicine<br />&bull; For some people, it may be necessary for the doctor to give a higher dose<br />&bull; For other people (for example the elderly, people with kidney or liver problems, an underactive adrenal or thyroid gland or prostate problems, and people that should not be sedated) the doctor may decide to use a lower dose<br />Your body may get used to the medicine (tolerance)<br />&bull; Do not take more than your doctor has prescribed<br />&bull; If you have been taking your medicine for some time you may find that it does not seem to be working as well as it did. If this happens, talk to your doctor<br />If you take more Oramorph than you should<br />If you take more of this medicine than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you. This is so the doctor knows what you have taken.<br />If you take more than you should, the following effects may happen:<br />&bull; The black circle in the centre of your eyes (pupil) gets smaller<br />&bull; You breathe more slowly<br />&bull; You have low blood pressure<br />People who have taken an overdose may also get pneumonia from inhaling vomit or foreign matter, symptoms of this may include breathlessness, cough or fever.<br />In more severe cases, very high doses could cause your blood circulation and breathing to slow down and cause unconsciousness for a long time, or even death. In children a high dose may cause fits (convulsions).<br />If you forget to take Oramorph<br />&bull; If you forget a dose, take it as soon as you remember it and take your next dose at the usual time<br />&bull; If it is nearly time for the next dose, skip the missed dose. This is because the time between doses should be at least 4 hours<br />&bull; Do not take a double dose to make up for a forgotten dose<br />If you stop taking Oramorph<br />Do not suddenly stop taking this medicine. If you want to stop taking this medicine, discuss this with your prescriber first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating may occur if you suddenly stop taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Oramorph can cause side effects, although not everybody gets them.<br />The following side effects may happen with this medicine, their frequency is not known:<br />Allergic reactions<br />If you have a severe allergic reaction, stop taking this medicine and see a doctor straight away. Signs may include swelling of the mouth and face, difficulty breathing, dizziness and skin reactions such as rash and itching.<br />Tell your doctor straight away if you notice the following side effects. You may need urgent medical treatment:<br />&bull; Having a headache. This could be a sign of increased pressure inside your skull<br />&bull; Feeling dizzy or unsteady when you stand up. This could be a sign of a temporary fall in blood pressure (orthostatic hypotension)<br />&bull; Shallow breathing, with a slow heartbeat (bradycardia) and cold clammy skin<br />&bull; Feeling restless, irritable or having changes in your mood<br />&bull; Stomach pain caused by spasm (cramps) of the tubes that carry urine to the bladder or bile to the intestines<br />&bull; Difficulty breathing (not linked to an allergic reaction)<br />&bull; Dry mouth or sweating<br />&bull; Seeing or hearing things that are not there (hallucinations) or feeling confused<br />&bull; Increased sensitivity to pain<br />&bull; Dependence and addiction (see section &ldquo;How do I know if I am addicted&rdquo;)<br />Drug Withdrawal<br />When you stop taking Oramorph, you may experience drug withdrawal symptoms, which include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating.<br />How do I know if I am addicted?<br />If you notice any of the following signs whilst taking Oramorph, it could be a sign that you have become addicted.<br />&bull; You need to take the medicine for longer than advised by your prescriber<br />&bull; You feel you need to use more than the recommended dose<br />&bull; You are using the medicine for reasons other than prescribed<br />&bull; When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again<br />If you notice any of these signs, it is important you talk to your prescriber<br />Other side effects<br />&bull; Feeling sick (nausea) or being sick (vomiting)<br />&bull; Constipation, which can be treated with appropriate laxatives<br />&bull; Difficulty in passing water (urine)<br />&bull; Feeling drowsy<br />&bull; Flushing of your face<br />&bull; Your heart rate getting faster (tachycardia) or slower (bradycardia) or fast and uneven (palpitations)<br />&bull; Lower body temperature (hypothermia)<br />&bull; Lowered sex drive or erection problems<br />&bull; Muscles feeling tense<br />&bull; The black circle in the centre of your eyes (pupil) getting smaller (miosis)<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.<br />By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton and on the label after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.<br />Do not store above 30&deg;C.<br />Once the bottle is opened, store below 25&deg;C.<br />After opening the bottle, Oramorph should be used within 3 months. Remember to write the date of first opening.<br />Keep the bottle in the outer carton in order to protect from light.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Each ml contains 20 mg of morphine sulfate as the active ingredient<br />&bull; The other ingredients are:<br />disodium edetate,<br />sodium benzoate (E211),<br />citric acid<br />purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Oramorph is a nearly colorless aqueous solution for oral use which is available in a dropper container with 20 ml solution.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>L. Molteni &amp; C. dei F.lli Alitti Societ&agrave; di Esercizio S.p.A.<br />Strada Statale 67, Localit&agrave; Granatieri, Scandicci (Florence)<br />Italy</p><p>This leaflet was last revised in: [to be completed]<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317- 2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />- Please contact the relevant competent authority.<br />This is a Medicament<br />- Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.<br />- Follow strictly the doctor‟s prescription, the method of use and the instructions of the pharmacist who sold the medicament.<br />- The doctor and the pharmacist are the experts in medicines, their benefits and risks.<br />- Do not by yourself interrupt the period of treatment prescribed for you.<br />- Do not repeat the same prescription without consulting your doctor.<br />- Keep all medicaments out of reach of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>الاسم الكامل للدواء هو أورامورف ٢٠ ملغم / مل محلول فموي. في هذه النشرة يستخدم الاسم<br />الأقصر ل أورامورف.<br /> تم وصف هذا الدواء لك لإزالة الألم الشديد.<br /> يحتوي هذا الدواء على مادة &quot;كبريتات المورفين&quot;، والتي تنتمي إلى مجموعة من الأدوية تسمى<br />&quot;المس ك نات الأفيونية&quot; المس كنة للألم.<br /> تم وصف هذا الدواء لك، فلا ينبغي اعطاؤه لأي شخص آخر.<br /> المواد الأفيونية يمكن أن تسب الإدمان، ويمكن أن تحدث أعراض الانسحاب لك إذا توقفت عن<br />تناوله فجأة. يجب&nbsp;أن يشرح طبيبك الخاص بك المدة التي ستستغرقها لتناول هذا الدواء، ومتى<br />يكون من المناسب&nbsp;التوقف ، وكيفية القيام بذلك بأمان.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم أورامورف:<br /> إذا كانت لديك حساسية من كبريتات المورفين أو لأي من المكونات الأخرى لهذا الدواء<br />(المدرجة في القسم 6) .</p><p>إذا كانت لديك مشاكل بالرئتين أو بالتنفس )قلة التهوية(، أو مرض الانسداد الرئوي<br />المزمن.<br /> إذا كنت تعاني من نوبات الربو.<br /> إذا كنت تعاني من مشاكل مفاجئة أو حديثة في الكبد.<br /> إذا عانيت مؤخرا من إصابة في الرأس.<br /> إذا كان لديك شيء يسمى &quot;ورم القواتم&quot;. هذا ورم نادر غير خبيث.<br /> إذا كنت تعاني من تشنجات (صرع) أو زيادة الضغط داخل الجمجمة.<br /> إذا كان الشخص الذي يتناول الدواء في حالة عميقة أو طويلة من عدم الوعي.<br /> إذا كنت مدمنا على الكحول أو قمت بشرب كمية كبيرة جدا من الكحول.<br /> إذا كنت تتعاطى الأدوية المثبطة لأكسيداز أحادي الأمين (التي تستخدم للاكتئاب) أو<br />تناولت منها بآخر أسبوعين.<br /> إذا كان لديك علوص شللي (فقدان حركة الأمعاء).<br />لا تتناول أورامورف إذا كان أي مما سبق ينطبق عليك. وإذا لم تكن متأكدا من ذلك، تحدث إلى<br />طبيبك أو الصيدلي قبل تناول أورامورف.<br />توخى عناية خاصة مع أورامورف<br />استشر طبيبك أو الصيدلي قبل تناول الدواء إذا كنت:<br />&bull; حاملا ا ، تحاولين الحمل أو في حالة الرضاعة الطبيعية.<br />&bull; خضعت لعملية جراحية خلال ال ٢٤ ساعة الماضية.<br />&bull; لديك مشكلة رئوية معينة تسبب ضيقاً&nbsp;في التنفس، تسمى انتفاخ الرئة أو لديك قصور في القل .<br />&bull; لديك صدمة (فشل في الدورة الدموية).<br />&bull; مصاب بالربو.<br />&bull; تعاني من مشاكل في المرارة.<br />&bull; تعاني من مشاكل طويلة الأمد (مزمنة) في الكبد أو الكلى.<br />&bull; رجلاً&nbsp;يعاني من مشاكل في البروستاتا.<br />&bull; تعاني من نقص الغدة الدرقية النشطة أو تورم الجلد (الوذمة المخاطية).<br />&bull; تعاني من وجود انحناء غير عادي في العمود الفقري (تقوس العمود الفقري).<br />&bull; لديك مشاكل في الأمعاء.<br />&bull; لديك نقص في نشاط الغدة الكظرية (قصور قشرة الكظر).<br />&bull; تعاني من زيادة الوزن بشكل كبير.<br />&bull; قد سبق وكنت مدمناً&nbsp;على المواد الأفيونية ، الكحول أو الأدوية الموصوفة أو العقاقير غير<br />المشروعة.<br />&bull; عانيت سابق اا من أعراض الانسحاب مثل الهياج أو القلق أو الاهتزاز أو التعر ق، عندما توقفت<br />عن تناول الكحول أو المخدرات.<br />إذا لم تكن متأكداً&nbsp;مما إذا كان أي مما سبق ينطبق عليك ، فتحدث إلى طبيبك أو الصيدلي قبل<br />تناول أورامورف.<br />تحذيرات واحتياطات:<br />تحدث مع طبيبك أو الصيدلي إذا كنت تعاني من أي من الأعراض التالية خلال استخدامك لدواء<br />أورامورف:<br />زيادة الحساسية للألم على الرغم من حقيقة أنك تأخذ جرعات متزايدة. سيقرر طبيبك ما إذا -<br />كنت ستحتاج إلى تغيير في الجرعة أو تغيير الى مسكن قوي. (انظر القسم 3 .)<br />الضعف أو التعب أو نقص الشهية أو الغثيان أو القيء أو انخفاض ضغط الدم. قد يكون هذا أحد -<br />أعراض الغدة الكظرية التي تنتج القليل جداا من هرمون الكورتيزول ، وقد تحتاج إلى تناول<br />مكملات هرمونية.<br />فقدان الرغبة الجنسية ، والعجز ، ووقف الحيض. قد يكون هذا بسبب انخفاض إنتاج هرمون -<br />الجنس.<br />تشعر أنك بحاجة إلى تناول المزيد من أورامورف للحصول على نفس المستوى من تخفيف -<br />الآلام ، وهذا قد يعني أنك أصبحت متحملا ا لتأثايرات هذا الدواء أو أصبحت مدمن اا عليه. تحدث<br />إلى طبيبك الذي سيناقش علاجك وقد يغير جرعتك أو يحولك إلى م س ك ن بديل للألم.<br />تنا ول هذا الدواء بانتظام ، وخاصة لفترة طويلة ، يمكن أن يؤدي إلى الإدمان. يجب أن يوضح -<br />طبيبك المدة التي ستستغرقها ومتى يكون من المناسب التوقف ، وكيفية القيام بذلك بأمان.<br />في حالات نادرة ، يمكن لزيادة جرعة هذا الدواء أن تجعلك أكثر حساسية للألم. إذا حدث هذا ، -<br />فأنت بحاجة إلى التحدث إلى طبيبك عن علاجك.<br />يمكن أن يسبب الإدمان أعراض الانسحاب عند التوقف عن تناول هذا الدواء. يمكن أن تشمل -<br />أعراض الانسحاب الأرق ، وصعوبة النوم ، والتهيج ، والإثاارة ، والقلق ، والشعور بضربات<br />القل (خفقان القلب )&nbsp;، وزيادة ضغط الدم ، والشعور بالتو عك ، والإسهال ، وفقدان الشهية ،<br />والارتعاش ، والرعشة أو التعرق. سيناقش طبيبك معك كيفية تقليل جرعتك تدريجي اا قبل إيقاف<br />الدواء. من المهم ألا تتوقف عن تناول الدواء فجأة حيث ستكون أكثر عرضة للإصابة بأعراض<br />الانسحاب.<br />يجب ألا تستخدم المواد الأفيونية إلا لمن وُصفَت لهم. لا تعط دوائك لأي شخص آخر. -<br />قد يؤدي تناول جرعات أعلى أو جرعات متكررة من مادة الأفيون إلى زيادة خطر الإدمان. -<br />يمكن أن يؤدي الإفراط في الاستخدام وسوء الاستخدام إلى جرعة زائدة و/ أو الوفاة.<br />أورامورف والأدوية الأخرى:<br />يرجی إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أدوية أخرى. وهذا يشمل<br />الأدوية التي تم الحصول عليها دون وصفة طبية والأدوية العشبية؛ وذلك لأن أورامورف يمكن<br />أن يؤثار على الطريقة التي تعمل بها بعض الأدوية الأخرى. كما أن بعض الأدوية الأخرى يمكن<br />أن تؤثار على طريقة عمل أورامورف.<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:<br /> الأدوية التي تساعدك على النوم وتجعلك تشعر بقلق أقل وتعمل على تهدئتك مثل<br />المهدئات، المُنوّمات، المسكّنات، مضادات الذهان، ومضادات الاكتئاب ثالاثاية الحلقة.<br />- يزيد تناول أورامورف مع الأدوية المهدئة مثل البنزوديازيبينات أو الأدوية ذات<br />الصلة من خطر النعاس وصعوبة التنفس (تثبيط الجهاز التنفسي) والغيبوبة وقد تكون<br />مهددة للحياة. لهذا السبب ، لا ينبغي أخذ أورامورف مع هذه الأنواع من الأدوية إلا<br />عندما تكون خيارات العلاج الأخرى غير ممكنة. ومع ذلك ، إذا وصف طبيبك<br />أورامورف مع الأدوية المهدئة ، يجب أن يحدد طبيبك جرعة ومدة تناول العلاجات<br />معاً.<br />- من فضلك أخبر طبيبك عن جميع الأدوية المهدئة التي تتناولها ، واتبع توصيات<br />طبيبك عن كثب . قد يكون من المفيد إبلاغ الأصدقاء أو الأقارب ليكونوا على دراية<br />بالعلامات والأعراض المذكورة أعلاه. اتصل بطبيبك إذا كنت تعاني من هذه<br />الأعراض.<br />&bull; أدوية التخدير المستخدمة أثاناء العمليات. -</p><p>&bull; دومبيريدون أو ميتوكلوبراميد أو فينوثايازين أدوية للشعور بالغثيان (الغثيان) والتوعّك -<br />(القيء).<br />&bull; ميكسيليتين و إسمولول - للتحكم في نظم القل .&nbsp;<br />&bull; ريتونافير - لعدوى فيروس نقص المناعة البشرية.&nbsp;<br />&bull; سيميتيدين - لقرحة المعدة وعسر الهضم وحرقة المعدة.&nbsp;<br />&bull; مثبطات مونوامين أوكسيديز ( MAOIs )- للاكتئاب.&nbsp;<br />&bull; ريفامبيسين - يستخدم لعلاج السل والتهابات أخرى.&nbsp;<br />&bull; جابابنتين - للصرع والألم طويل الأمد الناجم عن تلف الأعصاب.&nbsp;<br />&bull; الأدوية المستخدمة لعلاج الدم الجلطات (على سبيل المثال كلوبيدوجريل ، براسوجريل ،<br />تيكاجريلور) - قد يكون لها تأثاير متأخر ومنخفض عند تناولها مع المورفين.&nbsp;<br />أورامورف مع الغذاء والشراب:<br />ينبغي عليك تجنب شرب الكحول أثاناء تناول هذا الدواء.<br />الحمل والرضاعة الطبيعية<br />لا تأخذي أورامورف إذا كنتِ حاملاً&nbsp;أو تعتقدين أنك حامل ما لم تناقشي هذا الأمر مع طبيبك<br />واعتبار فوائد العلاج تفوق الضرر المحتمل للطفل. إذا كنتِ تستخدمين أورامورف أثاناء الحمل ،<br />فقد يصبح طفلك معتمداً&nbsp;ويعاني من أعراض الانسحاب بعد الولادة والتي قد تحتاج إلى علاج. لا<br />تتناولي أورامورف أثاناء الرضاعة لأن كبريتات المورفين تنتقل إلى حليب الثدي وستؤثار على<br />طفلك.<br />العمليات والتخدير<br />أخبر طبيبك أو الصيدلي إذا كنت ستخضع لعملية جراحية أو تخدير أو إذا أجريت عملية جراحية<br />أو تخدير خلال ال ٢٤ ساعة الماضية.<br />القيادة واستخدام الآلات<br />لا يجوز السياقة أو ركوب الدراجة أو استخدام أي أدوات أو آلات أثاناء تناول هذا الدواء. هذا<br />لأنك قد تشعر بالنعاس وتكون أقل يقظة أثاناء تناول هذا الدواء حتى عند الجرعات العادية. -<br />تحدث إلى طبيبك أو الصيدلي إذا لم تكن متأكد اا مما إذا كان من الآمن لك القيادة أثاناء تناول هذا<br />الدواء.<br />معلومات مهمة عن بعض مكونات أورامورف<br />بنزوات الصوديوم -<br />يحتوي هذا الدواء أيض اا على ١ ملغم بنزوات الصوديوم ( E211 ) في كل ١ مل ( ١٦ نقطة).<br />قد يزيد بنزوات الصوديوم من اليرقان )اصفرار الجلد والعينين( عند الأطفال حديثي الولادة<br />(حتى عمر ٤ أسابيع).<br />الصوديوم -<br />يحتوي هذا الدواء على أقل من ١ مليمول صوديوم ( ٢٣ ملغم) لكل ١ مل ( ١٦ نقطة) ، وهذا<br />يعني بشكل أساسي بأنه &quot;خالٍ&nbsp;من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم بتناول هذا الدواء تماما كما وصفه لك طبيبك. وإذا لم تكن متأكدا، قم بإستشارة الطبي أو<br />الصيدلي.<br />يج أن يناقش طبيبك معك إلى متى ستستمر فترة هذا الدواء. سيقوم طبيبك بترتي خطة لوقف<br />العلاج. سيحدد هذا كيفية تقليل الجرعة تدريجي اا والتوقف عن تناول الدواء.<br />طريقة الاستخدام<br />&bull; تناول هذا الدواء عن طريق الفم فقط.<br />&bull; افتح غطاء الزجاجة بالضغط لأسفل واللف في نفس الوقت.<br />&bull; لقياس الجرعة، قم ب ع د القطرات من زجاجة ال ٢٠ مل )قطرة واحدة = ١,٢٥ ملغم من<br />كبريتات المورفين(:<br />٤ قطرات = ٥ ملغم مورفين<br />٨ قطرات = ١٠ ملغم مورفين<br />١٦ قطرة = ٢٠ ملغم مورفين<br />٢٤ قطرة = ٣٠ ملغم مورفين<br />&bull; أغلق الزجاجة بإحكام مع الغطاء بمجرد سك الدواء.<br />&bull; قد تفضل إضافة جرعتك إلى مشروب غازي. إذا قمت بذلك ، يج ابتلاعها مباشرة بعد<br />الخلط.<br />لا تشرب مباشرة من الزجاجة لأن هذا قد يؤدي إلى تناول جرعة غير صحيحة )قليلة جد اا أو<br />أكثر من اللازم(. قد يؤدي تناول الكثير من هذا الدواء إلى جرعة زائدة مع احتمال حدوث<br />عواق وخيمة بما في ذلك فقدان الوعي وحتى الموت.<br />الجرعة<br />سيقرر طبيبك كمية الدواء التي سي عطيك إياها.<br />البالغين:<br />الجرعة الموصى بها هي ٨ &ndash; ١٦ قطرة من المحلول الفموي )والتي تعادل ١٠ - ٢٠ ملغم من<br />المورفين( كل ٤ ساعات.<br />الأطفال:<br />المراهقون من سن ١٣ إلى ١٨ عام ا : أقصى ما يج تناوله هو ٤ - ١٦ قطرة ) ٥ - ٢٠ ملغم(<br />كل ٤ ساعات.<br />الأطفال من سن ٦ إلى ١٢ عام ا : أقصى ما يج تناوله هو ٤ - ٨ قطرات ) ٥ - ١٠ ملغم( كل ٤<br />ساعات.<br />الأطفال من ١ إلى ٥ سنوات: أقصى ما يج تناوله هو ٤ قطرات ) ٥ ملغم( كل ٤ ساعات.<br />الأطفال أقل من عام: لا تع ط هذا الدواء للأطفال دون سن عام.<br />الحصول على قدر أكبر أو أقل من هذا الدواء<br />&bull; بالنسبة لبعض الأشخاص ، قد يكون من الضروري للطبي إعطاء جرعة أعلى.<br />&bull; للأشخاص الآخرين )على سبيل المثال كبار السن ، الأشخاص الذين يعانون من مشاكل في<br />الكلى أو الكبد ، أو الغدة الكظرية أو الغدة الدرقية أو مشاكل البروستاتا، والأشخاص الذين لا<br />ينبغي تسكينهم ب مس كن( قد يقرر الطبي استخدام جرعة أقل.</p><p>قد يعتاد جسمك على الدواء )الت ح م ل(<br />&bull; لا تأخذ أكثر مما وصفه طبيبك.<br />&bull; إذا كنت تتناول دوائك لبعض الوقت ، فقد تجد أنه لا يبدو أنه يعمل بالشكل المطلوب. إذا حدث<br />هذا ، تحدث إلى طبيبك.<br />إذا تناولت المزيد من أورامورف أكثر مما يجب<br />إذا تناولت كمية أكبر من هذا الدواء ، فتحدث إلى الطبي أو اذه إلى المستشفى على الفور. خذ<br />علبة الدواء معك، حتى يعرف الطبي ما تناولته.<br />إذا تناولت أكثر مما ينبغي ، فقد تحدث التأثايرات التالية:<br />&bull; تصبح الدائرة السوداء في وسط عينيك )الحدقة( أصغر.<br />&bull; تتنفس ببطء أكثر.<br />&bull; لديك انخفاض في ضغط الدم.<br />قد يصاب الأشخاص الذين تناولوا جرعة زائدة أيض اا بالتهاب رئوي من استنشاق القيء أو المواد<br />الغريبة ، قد تشمل أعراض ذلك ضيق التنفس والسعال أو الحمى. في الحالات الأكثر شدة ، قد<br />تتسب الجرعات العالية جد اا في إبطاء الدورة الدموية والتنفس وتسب فقدان الوعي لفترة طويلة<br />، أو حتى الموت. عند الأطفال ، قد تسب جرعة عالية نوبات )تشنجات(.<br />إذا نسيت تناول أورامورف<br />&bull; إذا نسيت جرعة ، فتناولها بمجرد أن تتذكرها وتناول الجرعة التالية في الوقت المعتاد.<br />&bull; إذا كان الوقت قد حان للجرعة التالية ، فتجاوز الجرعة الفائتة. وذلك لأن الوقت بين الجرعات<br />يج أن يكون على الأقل ٤ ساعات.<br />&bull; لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.<br />إذا توق فت عن تناول أورامورف<br />لا تتوقف فجأة عن تناول هذا الدواء. إذا كنت تريد التوقف عن تناول هذا الدواء ، فناقش ذلك مع<br />طبيبك أولاا. سيخبرك بكيفية القيام بذلك ، عادةا عن طريق تقليل الجرعة تدريجي اا بحيث يتم تقليل<br />أي آثاار انسحاب غير سارة إلى الحد الأدنى. قد تحدث أعراض الانسحاب مثل الأرق ، وصعوبة<br />النوم ، والتهيج ، والإثاارة ، والقلق ، والشعور بضربات القل )خفقان القل ( ، وزيادة ضغط الدم<br />، والشعور بالتو عك ، والإسهال ، والرعشة ، أو التعرق، إذا توقفت فجأة عن تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية ، يمكن أن يسب أورامورف آثاار اا جانبية ، على الرغم من عدم حدوثاها لدى<br />الجميع. الآثاار الجانبية التالية قد تحدث مع هذا الدواء ، وتواترها غير معروف:<br />ردود الفعل التحسسية: إذا كان لديك رد فعل تحسسي شديد ، توقف عن تناول هذا الدواء<br />واستشر الطبي على الفور. قد تشمل العلامات تو ر م الفم والوجه وصعوبة التنفس والدوخة<br />وتفاعلات جلدية مثل الطفح الجلدي والحكة.<br />أخبر طبيبك على الفور إذا لاحظت الآثار الجانبية التالية. فقد تحتاج إلى علاج طبي عاجل:<br />&bull; الإصابة بالصداع. قد يكون هذا علامة على زيادة الضغط داخل جمجمتك.<br />&bull; الشعور بالدوار أو عدم الاستقرار عند الوقوف. قد يكون هذا علامة على انخفاض مؤقت في<br />ضغط الدم (انخفاض ضغط الدم الوضعي).<br />&bull; التنفس الضحل ، مع بطء ضربات القل (بطء القلب) وبرودة الجلد.<br />&bull; الشعور بالضيق أو الانفعال أو حدوث تغيرات في مزاجك.</p><p>&bull; ألم المعدة الناجم عن تشنج )تقلصات( الأنابي التي تحمل البول إلى المثانة، أو التي تحمل<br />الصفراء إلى الأمعاء.<br />&bull; صعوبة في التنفس (غير مرتبط برد الفعل التحسسي).<br />&bull; جفاف الفم أو التعرّ&nbsp;ق.<br />&bull; رؤية أو سماع أشياء غير موجودة (الهلوسة) أو الشعور بالارتباك.<br />&bull; زيادة الحساسية تجاه الألم.<br />&bull; الاعتماد والإدمان (انظر قسم &quot;كيف أعرف أنني مُدمن&quot;).<br />انسحاب الدواء<br />عند التوقف عن تناول أورامورف ، قد تواجه أعراض انسحاب الدواء ، والتي تشمل الأرق ،<br />وصعوبة النوم ، والتهيج ، والإثاارة ، والقلق ، والشعور بضربات قلبك (خفقان القلب) ، وزيادة<br />ضغط الدم ، والشعور بالتو ع ك ، والإسهال ، والرجفان ، والرعشة. التعرق.<br />كيف أعرف أنني م دمن؟<br />إذا لاحظت أياً من العلامات التالية أثاناء تناولك لأورامورف ، فقد تكون علامة على أنك أصبحت<br />مدمن اا:<br />&bull; تحتاج إلى تناول الدواء لفترة أطول مما ينصح به طبيبك.<br />&bull; تشعر أنك بحاجة إلى استخدام أكثر من الجرعة الموصى بها.<br />&bull; أنك تستخدم الدواء لأسباب غير موصوفة.<br />&bull; عندما تتوقف عن تناول الدواء تشعر أنك لست على ما يرام ، بينما تشعر بتحسن بمجرد تناول<br />الدواء مرة أخرى.<br />إذا لاحظت أي اا من هذه العلامات ، فمن المهم أن تتحدث مع طبيبك.<br />الآثار الجانبية الأخرى<br />&bull; الشعور بالغثيان أو المرض (القيء).<br />&bull; الإمساك ، الذي يمكن علاجه بالمل ي نات المناسبة.<br />&bull; صعوبة مع تمرير الماء (البول).<br />&bull; الشعور بالنعاس.<br />&bull; احمرار الوجه.<br />&bull; تسارع معدل ضربات القل (تسر ّع القلب ) أو تباطؤ (بطء القلب ) أو سريع وغير منتظم<br />(خفقان القلب).<br />&bull; انخفاض درجة حرارة الجسم.<br />&bull; انخفاض الدافع الجنسي أو مشاكل الانتصاب.<br />&bull; الشعور بالتوتر في العضلات.<br />&bull; تقلص الدائرة السوداء في مركز العين (حدقة العين) (انقباض الحدقة).<br />الإبلاغ عن الآثار الجانبية:<br />إذا تعرضت لأي من الآثاار الجانبية، تكلم مع طبيبك أو الصيدلي. قد يشمل هذا أي آثاار جانبية<br />محتملة غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الآثاار الجانبية، يمكنك المساعدة في<br />تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بهذا الدواء بعيدا عن نظر ومتناول الأطفال.</p><p>لا تستخدم الدواء بعد تاريخ انتهاء الصلاحية الذي يظهر علی الکرتون وعلی الملصق<br />بعد علامة &quot; Exp &quot; حيث يشير التاريخ الموضح بعدها إلى انتهاء الصلاحية وهو آخر<br />يوم من ذلك الشهر.<br /> لا تخزن فوق ٣٠ درجة مئوية.<br /> بمجرد فتح الزجاجة، تحفظ في درجة حرارة أقل من ٢٥ درجة مئوية.<br /> يستخدم في غضون ٣ أشهر من يوم فتحه الأول. تذكر أن تكت تاريخ فتحه الأول.<br /> قم بتخزين الزجاجة في الكرتون الخارجي لحمايتها من الضوء.<br /> لاتتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل<br />الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها، حيث ستساعد هذه<br />التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كل ١ مل من المحلول الفموي تحتوي على ٢٠ ملغم من كبريتات المورفين كمادة فعالة.<br />- المكونات الأخرى هي: إيديتات ثانائي الصوديوم، بنزوات الصوديوم )إي 211 ،)<br />حامض الستريك، ماء منقى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أورامورف هو محلول نقي وعديم اللون من أجل الاستخدام عبر الفم ومعبأ بقطارة ٢٠ مل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>L. Molteni &amp; C. dei F.lli Alitti Societ&agrave; di Esercizio S.p.A. &ndash; Strada Statale 67 , Localit&agrave; Granatieri &ndash; Scandicci (Florence) &ndash;<br />ايطاليا</p><p>&nbsp;</p><p>للإبلاغ عن أي آثار جانبية:<br />&bull; المملكة العربية السعودية:<br />المركز الوطني للتيقظ والسلامة الدوائية:<br />فاكس: - +966-11-205-7662<br />للإتصال على المركز: - +966-11-2038222 ، Exts: 2317-2356-2353-2354-2334-2340<br />الهاتف المجاني: - 8002490000<br />البريد الإلكتروني: - npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: - www.sfda.gov.sa/npc<br /> دول مجلس التعاون الخليجي الأخرى:<br />يرجى الاتصال بالسلطة المختصة والمعنية<br />9<br />عن هذا دواء<br />- الدواء هو منتج يؤثار على صحتك واستهلاكه خلافا للتعليمات أمر خطير بالنسبة لك.<br />- اتبع وصفة الطبي ، وطريقة الاستخدام وتعليمات الصيدلي الذي باع الدواء.<br />- الطبي والصيدلي هم الخبراء في مجال الأدوية وفوائدها ومخاطرها.<br />- لا تقم من تلقاء نفسك بوقف فترة العلاج المقررة لك.<br />- لا تكرر نفس الوصفة الطبية دون استشارة الطبي .<br />- تحفظ جميع الأدوية بعيد اا عن متناول الأطفال.<br />مجلس وزراء الصحة العرب<br />اتحاد الصيادلة العرب</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oramorph 20 mg/ml oral solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml aqueous solution contains 20 mg of Morphine sulfate
1 drop corresponds to 1.25 mg morphine sulfate.
Excipient(s) with known effect
Sodium benzoate (E 211) 1 mg/ml
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral solution.
Nearly colourless aqueous solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the relief of severe pain in adults, adolescents (aged 13-18 years) and children (aged 1-12 years).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults: Recommended dose 10-20 mg (8-16 drops) every 4 hours.<br />Maximum daily dose: 120 mg per day.<br />Paediatric population:<br />Adolescents 13 - 18 years: Recommended dose 5-20 mg (4-16 drops) every 4 hours.<br />Maximum daily dose: 120 mg per day<br />Children 6-12 years: Recommended dose 5-10 mg (4-8 drops) every 4 hours.<br />Maximum daily dose: 60 mg per day<br />Children 1-5 years: Recommended dose 5 mg (4 drops) every 4 hours.<br />Maximum daily dose: 30 mg per day.<br />Children under 1 year: Not recommended.</p><p>Under medical control the dose can be increased depending on the severity of pain and depending on the previous use of analgesics.<br />Special populations:<br />Reductions in dosage may be appropriate in the elderly and in patients with chronic hepatic disease (for acute hepatic disease see section 4.3), renal impairment, severe hypothyroidism, adrenocortical insufficiency, prostatic hypertrophy, shock or where sedation is undesirable.<br />Discontinuation of therapy<br />Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with Oramorph in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).<br />Method of Administration<br />For oral use<br />The dose is determined by counting the drops from the 20 ml bottle (1 drop = 1.25 mg morphine sulfate):<br />4 drops = 5 mg morphine sulfate<br />8 drops = 10 mg morphine sulfate<br />16 drops = 20 mg morphine sulfate<br />24 drops = 30 mg morphine sulfate<br />After withdrawal of the medicine the bottle is closed again with the screw closure.<br />The required dose may be added to a soft drink immediately prior to administration..<br />Correspondence between the different routes of administration:<br />When patients are transferred from other morphine preparations to Oramorph dosage titration may be appropriate.<br />Morphine sulfate is readily absorbed from the gastro-intestinal tract following oral administration. However, when oral Oramorph preparations are used in place of parenteral morphine, a 50 % to 100 % increase in dosage is usually required in order to achieve the same level of analgesia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oramorph is contraindicated in:
• patients known to be hypersensitivity to morphine sulfate or to any of the excipients listed in section 6.1
• respiratory insufficiency or respiratory depression, obstructive airways disease
• paralytic ileus (see section 4.4)
• acute liver disorders (hepatitis, hepatic porphyria)
• acute alcohol intoxication
• head injury and conditions with increased intracranial pressure (see section 4.4)
• coma (see section 4.4)
• convulsive disorders
• concurrent administration with monoamine oxidase (MAO) inhibitors or within 2 weeks of discontinuation of treatment with MAO (see section 4.5)
• patients with phaeochromocytoma. Morphine and some other opioids can induce the release of endogenous histamine and thereby stimulate catecholamine release
• acute asthma exacerbations (see section 4.4 for information relating to use in controlled asthma)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The medicine should be used carefully in the following patient groups:<br />&bull; in the first 24 hours post-operatively<br />&bull; in hypothyroidism (see section 4.2)</p><p>&bull; In patients with obstructive respiratory disorders, reduced respiratory reserve (e.g. kyphoscoliosis, emphysema, cor pulmonale or severe obesity)<br />Asthma<br />It has been suggested that opioids can be used with caution in controlled asthma. However, opioids are contraindicated in acute asthma exacerbations (see section 4.3).<br />Head injury and increased intracranial pressure<br />Oramorph is contraindicated in patients with increased intracranial pressure, head injuries and coma (see section 4.3). The capacity of morphine to elevate cerebrospinal fluid pressure may be greatly increased in the presence of already elevated intracranial pressure produced by trauma. Also, morphine may produce confusion, miosis, vomiting and other adverse reactions which may obscure the clinical course of patients with head injury.<br />Abdominal conditions<br />Morphine sulfate must not be given if paralytic ileus is likely to occur (see section 4.3), or if the patient has bowel or obstructive biliary disease. Should paralytic ileus be suspected or occur during use, Oramorph should be discontinued immediately.<br />Caution should be exercised where there is an obstructive bowel disorder, biliary colic, operations on the biliary tract, acute pancreatitis or prostatic hyperplasia.<br />If constipation occurs this may be treated with the appropriate laxatives.<br />Care should be exercised in patients with inflammatory bowel disease.<br />Morphine may obscure the diagnosis or clinical course of patients with acute abdominal conditions and complications following abdominal surgery.<br />Hypotensive effect<br />The administration of morphine can lead to a severe decrease in blood pressure in patients with impaired capability of maintaining homeostatic blood pressure e.g. decreased blood volume, concomitant administration of phenothiazines or certain anaesthetics (see section 4.5).<br />Drug dependence, tolerance and potential for abuse<br />Morphine sulfate is an opioid agonist and controlled drug.<br />For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g., major depression).<br />Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.<br />A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.<br />Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient.<br />Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.<br />Morphine sulfate may be abused by inhaling or injecting the product. These practices pose a significant risk to the abuser that could result in overdose and death.<br />Patients should be closely monitored for signs of misuse, abuse, or addiction.</p><p>Morphine has an abuse potential similar to other strong agonist opioids, and should be used with particular caution in patients with a history of alcohol or drug abuse.<br />The clinical need for analgesic treatment should be reviewed regularly.<br />Drug withdrawal syndrome<br />Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with Oramorph.<br />Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.<br />The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.<br />If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.<br />Hyperalgesia<br />Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain.<br />Hyperalgesia that does not respond to a further dose increase of morphine may occur in particular in high doses. A morphine dose reduction or change in opioid may be required.<br />Hypersensitivity<br />Hypersensitivity and anaphylactic reactions have both occurred with the use of Oramorph. Care should be taken to elicit any history of allergic reactions to opiates. Oramorph is contraindicated in patients known to be hypersensitive to morphine sulfate (see section 4.3).<br />Adrenal insufficiency<br />Opioid analgesics may cause reversible adrenal insufficiency requiring monitoring and glucocorticoid replacement therapy. Symptoms of adrenal insufficiency may include e.g. nausea, vomiting, loss of appetite, fatigue, weakness, dizziness, or low blood pressure.<br />Decreased sex hormones and increased prolactin<br />Long-term use of opioid analgesics may be associated with decreased sex hormone levels and increased prolactin. Symptoms include decreased libido, impotence or amenorrhea.<br />Risk in special populations<br />Morphine is metabolised by the liver and should be used with caution in patients with hepatic disease as oral bioavailability may be increased. It is wise to reduce dosage in chronic hepatic and renal disease, severe hypothyroidism, adrenocortical insufficiency, prostatic hypertrophy or shock (see section 4.2).<br />The active metabolite Morphine-6-glucuronide may accumulate in patients with renal failure, leading to CNS and respiratory depression.<br />Acute chest syndrome (ACS) in patients with sickle cell disease (SCD)<br />Due to a possible association between ACS and morphine use in SCD patients treated with morphine during a vaso-occlusive crisis, close monitoring for ACS symptoms is warranted.<br />Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs<br />Concomitant use of Oramorph and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death.</p><p>Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Oramorph concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.<br />The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).<br />Oral P2Y12 inhibitor antiplatelet therapy<br />Within the first day of concomitant P2Y12 inhibitor (e.g. clopidogrel, prasugrel, ticagrelor) and morphine treatment, reduced efficacy of P2Y12 inhibitor treatment has been observed (see section 4.5).<br />Excipient related warnings<br />This medicine also contains 1 mg sodium benzoate (E211) in each 1 ml. Sodium benzoate may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).<br />This medicine contains less than 1 mmol sodium (23 mg) per ml (16 drops), that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Monoamine oxidase inhibitors<br />Monoamine oxidase inhibitors are known to interact with narcotic analgesics producing CNS excitation or depression with hyper- or hypotensive crisis, therefore their concomitant use with Oramorph is contraindicated (see section 4.3).<br />Gabapentin<br />Interactions have been reported in those taking morphine and gabapentin concomitantly. Reported interactions suggest an increase in opioid adverse events, the mechanism of which is not known. Caution should be taken where these medicines are prescribed concomitantly.<br />In a study involving healthy volunteers (N=12), when a 60 mg controlled-release morphine capsule was administered 2 hours prior to a 600 mg gabapentin capsule, mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine. Therefore, patients should be carefully observed for signs of CNS depression, such as somnolence, and the dose of gabapentin or morphine should be reduced appropriately.<br />Ritonavir<br />Although there are no pharmacokinetic data available for concomitant use of ritonavir with morphine, ritonavir may increase the activity of glucuronyl transferases. Consequently, co- administration of ritonavir and morphine may result in decreased serum concentrations of morphine with possible loss of analgesic effectiveness.<br />Rifampicin<br />Rifampicin can reduce the serum concentration of morphine and decrease its analgesic effect, the mechanism of which is not known.<br />The analgesic effect of morphine should be monitored and doses of morphine adjusted during and after treatment with rifampicin.<br />Cimetidine<br />Cimetidine inhibits the metabolism of morphine.<br />CNS depressants<br />The concomitant application of tranquilisers, anaesthetics (see section 4.4), sedatives, antipsychotics, tricyclic antidepressants, and alcohol increases the CNS depressing effect of morphine, especially the depressive effect on respiration.</p><p>Sedative medicines such as benzodiazepines or related drugs<br />The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).<br />Esmolol<br />Morphine may increase plasma concentrations of esmolol.<br />Domperidone/metoclopramide<br />Opioid analgesics including morphine may antagonise the actions of domperidone and metoclopramide on gastro-intestinal activity.<br />Mexiletine<br />The absorption of mexiletine may be delayed by concurrent use of morphine.<br />Phenothiazine antiemetics<br />Phenothiazine antiemetics may be given with morphine. However, hypotensive effects have to be considered (see section 4.4).<br />Oral Anticoagulants<br />A delayed and decreased exposure to oral P2Y12 inhibitor antiplatelet therapy has been observed in patients with acute coronary syndrome treated with morphine. This interaction may be related to reduced gastrointestinal motility and apply to other opioids. The clinical relevance is unknown, but data indicate the potential for reduced P2Y12 inhibitor efficacy in patients co-administered morphine and a P2Y12 inhibitor (see section 4.4).<br />In patients with acute coronary syndrome, in whom morphine cannot be withheld and fast P2Y12 inhibition is deemed crucial, the use of a parenteral P2Y12 inhibitor may be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Although morphine sulfate has been in general use for many years, there is inadequate evidence of safety in human pregnancy.<br />Morphine is known to cross the placenta. Therefore, Oramorph should not be used in pregnancy, especially the first trimester unless the expected benefit is thought to outweigh any possible risk to the foetus.<br />Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.<br />If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.<br />Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.<br />The risk of gastric stasis and inhalation pneumonia is increased in the mother during labour. Since morphine rapidly crosses the placental barrier it should not be used during the second stage of labour or in premature delivery because of the risk of secondary respiratory depression in the newborn infant.<br />Breast-feeding<br />Although morphine sulfate has been in general use for many years, there is inadequate evidence of safety during lactation.</p><p>Administration to nursing women is not recommended as morphine sulphate may be secreted in breast milk and may cause respiratory depression in the infant.<br />Fertility<br />Long term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility and erectile dysfunction.<br />Animal studies have shown that morphine may reduce fertility (see 5.3. preclinical safety data).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oramorph has major influence on the ability to drive and use machines, as it may cause drowsiness and reduce alertness. This is to be expected especially upon initiation of treatment, dose increase and change in medication as well as in combination with alcohol and centrally depressing substances.<br />Patients should not drive or use machines while taking Oramorph.<br />The time after which such activities may be safely resumed is extremely patient-dependent and must be decided by the physician.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In normal doses, the commonest side effects of morphine sulfate are nausea, vomiting, constipation, drowsiness and confusion. If constipation occurs, this may be treated with appropriate laxatives. The effects of morphine have led to its abuse and misuse. Dependence and addiction may develop with regular use.<br />Data from clinical trials are not available. Therefore it is not possible to provide information on the frequencies of undesirable effects, except where stated. A full list of currently known adverse reactions is presented below:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:249px"><strong>SOC Category</strong></td><td style="width:250px"><strong>Side effect</strong></td></tr><tr><td style="width:249px">Immune system disorders</td><td style="width:250px">Hypersensitivity<br />Anaphylactic reaction (see section 4.4)<br />Anaphylactoid reactions</td></tr><tr><td style="width:249px">Psychiatric disorders</td><td style="width:250px">Confusional state Restlessness<br />Altered mood Hallucination<br />Dependence (see section 4.4)</td></tr><tr><td style="width:249px">Nervous system disorders</td><td style="width:250px">Somnolence<br />Headache<br />Increased intracranial pressure (see section 4.4) Allodynia<br />Hyperalgesia (see section 4.4)</td></tr><tr><td style="width:249px">Eye Disorders</td><td style="width:250px">Miosis</td></tr><tr><td style="width:249px">Ear and labyrinth disorders</td><td style="width:250px">Vertigo</td></tr><tr><td style="width:249px">Respiratory, thoracic and mediastinal disorders</td><td style="width:250px">Respiratory depression (see section 4.4 and section 4.6)</td></tr><tr><td style="width:249px">Cardiac disorders</td><td style="width:250px">Bradycardia<br />Tachycardia<br />Palpitations</td></tr><tr><td style="width:249px">Vascular disorders</td><td style="width:250px">Hypotension<br />Flushing</td></tr><tr><td style="width:249px">Gastrointestinal disorders</td><td style="width:250px">Nausea<br />Vomiting<br />Constipation (see section 4.4)<br />Dry mouth</td></tr><tr><td style="width:249px">General disorders and administration site conditions</td><td style="width:250px">Hypothermia<br />Drug tolerance (see section 4.4)<br />Drug withdrawal syndrome* (see section 4.4 and section 4.6)</td></tr><tr><td style="width:249px">Hepatobiliary Disorders</td><td style="width:250px">Biliary colic</td></tr><tr><td style="width:249px">Skin and subcutaneous tissue disorders</td><td style="width:250px">Urticaria<br />Pruritus<br />Hyperhidrosis</td></tr><tr><td style="width:249px">Musculoskeletal and connective tissue disorders</td><td style="width:250px">Muscle rigidity</td></tr><tr><td style="width:249px">Renal and urinary disorders</td><td style="width:250px">Dysuria<br />Ureteral spasm<br />Oliguria</td></tr><tr><td style="width:249px">Reproductive system and breast disorders</td><td style="width:250px">Decreased libido<br />Erectile dysfunction</td></tr></tbody></table><p>*Frequency uncommon (&ge; 1/1,000 to &lt; 1/100)<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any side effect(s):<br />&bull; Saudi Arabia:<br />-The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />-Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.<br />Symptoms:<br />Signs of morphine toxicity and overdosage are likely to consist of pin-point pupils, respiratory depression and hypotension.<br />Circulatory failure, pneumonia aspiration and deepening coma may occur in more severe cases.<br />Convulsions may occur in infants and children.<br />Death may occur from respiratory failure.<br />Treatment<br />Adults: Administer 0.4-2 mg of naloxone intravenously. Repeat at 2-3 minute intervals as necessary to a maximum of 10 mg, or by 2 mg in 500 ml of normal saline or 5 % dextrose (4 micrograms/ml).<br />Children: 5-10 micrograms per kilogram body weight intravenously. If this does not result in the desired degree of clinical improvement, a subsequent dose of 100 mcg/kg body weight may be administered.<br />Care should always be taken to ensure that the airway is maintained. Assist respiration if necessary.<br />Maintain fluid and electrolyte levels. Oxygen, i.v. fluids, vasopressors and other supportive measures should be employed as indicated. Peak plasma concentrations of morphine are expected to occur within 15 minutes of oral ingestion. Therefore gastric lavage and activated charcoal are unlikely to be beneficial.<br />Caution: the duration of the effect of naloxone (2-3 hours) may be shorter than the duration of the effect of the morphine overdose. It is recommended that a patient who has regained consciousness after naloxone treatment should be observed for at least 6 hours after the last dose of naloxone.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Natural opium alkaloids<br />ATC code: N02AA01<br />Morphine binds to specific receptors located in the CNS and in various peripheral organs. Pain sensation and affective reaction to the pain is reduced by interaction with CNS receptors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Morphine sulfate is readily absorbed from the gastrointestinal tract following oral administration. Following oral administration of radiolabelled morphine sulfate to humans, peak plasma levels were reached after approximately 15 minutes. Morphine undergoes significant first pass metabolism in the liver resulting in a systemic bioavailability of approximately 25% (range 15-49%).<br />Distribution<br />Morphine is distributed throughout the body but found mainly in the kidneys, liver, lung and spleen with lower concentrations being found in the brain and muscles. Approximately one third of morphine in the plasma is protein bound after a therapeutic dose. Morphine diffuses across the placenta and traces of the drug appear in breast milk.<br />Biotransformation<br />Metabolism of morphine principally involves conjugation to morphine 3- and 6- glucuronides. Small amounts are also metabolised by N-demethylation and O-methylation. Morphine-6- glucuronide has pharmacological effects indistinguishable from those of morphine. The half-life of morphine is approximately 2 hours. The half-life of morphine-6-glucuronide is somewhat longer.<br />Elimination<br />About 10 % of a dose of morphine is excreted through the bowel into the faeces. The remainder is excreted in the urine, mainly in the form of conjugates. About 90 % of a single dose of morphine is excreted in 24 hours. Enterohepatic circulation of morphine and its metabolites can occur, and may result in small quantities of morphine being present in the urine or faeces several days after the last dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In male rats, reduced fertility and chromosomal damage in gametes have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium edetate<br />Sodium benzoate (E 211)<br />Citric acid<br />Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
Shelf-life after first opening: 3 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.<br />Once the bottle is opened, store below 25&deg;C.<br />Keep the product in the original package to protect it from the light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber coloured glass (type III Ph.Eur.) bottle with 20 ml of oral solution, closed with tamper evident child resistant HDPE screw cap and integrated LDPE dropper.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The unused product must be disposed off in accordance with the local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A
Strada Statale 67 Fraz. Granatieri
Scandicci (Firenze)
Italy
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>